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SDC were $AU37,491 and $AU33,360, respectively, with an in-
cremental cost of $AU4,131. The AUC0-inﬁnity was 6.5 and 3.5
patient life-years, respectively, leading to an incremental beneﬁt of
3.0 life-years gained. This gives an ICER of $AU1,377 per dis-
counted life-year gained. Compared with published studies of IC-
ERs for HDC versus SDC in multiple myeloma and metastatic
breast cancer, these results support HDC as a cost-effective treat-
ment in relapsed aggressive NHL.
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PHASE II TRIAL OF GM-CSF AS MAINTENANCE THERAPY POST–AU-
TOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN
MULTIPLE MYELOMA
Mandanas, R.A., Beveridge, R., Rifkin, R.M., Greenspan, A.R.,
Orloff, G.J., Klein, L.M., Rauch, M.A., Boehm, K.A., Zhan, F.,
Asmar, L. US Oncology Research, Inc., Houston, TX.
Background: It has been hypothesized that GM-CSF may stim-
ulate monocytes and dendritic cells, resulting in an increased im-
mune-mediated recognition and cytotoxic effect against myeloma.
Methods: Forty study subjects, who did not show progression
within the ﬁrst 120 days following their autotransplantations, were
enrolled at 9 sites throughout the US Oncology transplantation
network. The median age was 59.2 years (range, 42.4–78.7 years),
67.5% were male, 32.5% were white, and the PS scores (0/1) were
62.5% and 37.5%, respectively. Participants were instructed on the
proper technique for giving themselves subcutaneous (SC) injec-
tions at their ﬁrst dose visit. Subsequently, subjects self-adminis-
tered 250 g GM-CSF (Leukine, Berlex Laboratories, Seattle,
WA) SC daily for days 1–14 of each 28-day cycle, for a total of 1
year. Nonhematologic toxicities were managed symptomatically if
they were grade 2 (excluding nausea and alopecia); for toxici-
ties  grade 3, the treatment was withheld until the event recov-
ered to  grade 1. For WBC count  20,000/mL or platelet
count  500,000/mL, doses of GM-CSF were reduced by 50% (to
125 g). Results: There were 40 eligible participants. At 1 year
from transplantation, 12 subjects relapsed or died, and the product-
limit estimated progression-free survival rate (PFS) was 65.1% (vs
60% in unpublished data). The 2-year PFS was 50.6% (vs 40% in
unpublished data). The median PFS was 16.3 months (range,
5–25.3 months), and at 2 years, the estimated survival was 84%.
Toxicity was limited. Grade 3 or 4 treatment-related events in-
cluded dyspnea and bone pain (5% each) and myalgia and chest
pain (2.5% each). There were 4 deaths; none were treatment-
related. Conclusions: Administration of GM-CSF posttransplan-
tation for myeloma is feasible and may delay progression of the
disease.
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ALLOGENEIC STEM CELL TRANSPLANTATION (SCT) USING REDUCED
INTENSITY CONDITIONING (RIC) IN THE PATIENTS WITH RECURRENT
AND REFRACTORY MALIGNANT LYMPHOPROLIFERATIVE DISORDERS
Raida, L.1, Faber, E.1, Papajik, T.1, Indrak, K.1, Zapletalova, J.2,
Vitek, A.3, Koza, V.4 1Hemato-oncology Department, University Hos-
pital, Olomouc, Czech Republic; 2Centre of Biomedical Information,
Medical School of Palacky University, Olomouc, Czech Republic; 3Insti-
tute of Hematology and Blood Transfusion, Prague, Czech Republic;
4Hemato-oncology Department, University Hospital, Pilsen, Czech Re-
public.
Background: An evidence of graft versus tumor (GvT) effect
revealed a new therapeutic opportunity for conventionally incur-
able patients suffering from lymphoid malignancies. RIC allows us
to achieve the engraftment of donor immunocompetent cells and
to avoid unnecessary toxicity in usually heavily pretreated patients.
We present a cohort of patients allografted after RIC because of
recurrent/refractory malignant lymphoproliferation. Methods:
Nineteen patients (median age, 50 years; range, 33–68 years) with
recurrent/refractory malignant lymphoproliferations (5 cases of
B-CLL [26%], 12 cases of B-NHL [63%], 2 cases of T-NHL
[11%]) were allografted after ﬂudarabine-based RIC. Fifteen pa-
tients (79%) received SCT from sibling donors; 4 (21%), from
unrelated donors. Cyclosporin-A (CSP) was administered as sin-
gle-agent GvHD prophylaxis in 8 (42%) patients. A combination
with methotrexate (MTX) and mycophenolate mofetil (MMF) was
used in 6 (32%) and 5 (26%) patients, respectively. The immuno-
suppression was gradually tapered and stopped between days 30
and 180 based on the therapeutic response, chimerism, and
GvHD development. The median follow-up is 12 months (range,
1–33 months). Results: Seventeen (90%) recipients achieved com-
plete remission (CR) of disease. After SCT, disease relapse and
progression were observed in 4 (21%) and 2 (11%) patients, re-
spectively. Thirteen (68%) patients developed acute, chronic, or
both forms of GvHD. Nine (48%) recipients died. The causes of
death were disease progression in 3 patients (16%) and transplan-
tation-related complications in 6 patients (32%). Estimated 2-year
event-free survival (EFS) was 30%, and estimated overall survival
(OS) was 47%. Conclusions: Our results conﬁrm the evidence of
GvT reaction and effective tumor control in otherwise incurable
patients treated with allografting after RIC. The major problem
remains GvHD and related complications responsible for signiﬁ-
cant morbidity and mortality.
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SALVAGE THERAPY WITH CDME SCHEDULE FOLLOWED BY PBSC
TRANSPLANTATION IN 20 LYMPHOMA PATIENTS: AN INTENTION-TO-
MOBILIZE AND TRANSPLANTATION ANALYSIS
Won, J.-H., Kim, H.-J., Lee, N.-S., Lee, S.-H., Bae, S.-B.,
Kim, C.-K., Lee, K.-T., Park, S.-K., Hong, D.-S., Park, H.-S. Division
of Hematology-Oncology and Institute for Clinical Molecular Biology
Research, Soon Chun Hyang University College of Medicine, Seoul,
Korea.
The combination of mitoxantrone, etoposide, cisplatin, and
dexamethasone (CDME regimen) is an effective salvage regimen
for lymphoproliferative disease. Our study analyzed this combina-
tion in mobilization of peripheral blood stem cells in patients with
relapsed, refractory, or high-risk lymphoma. The study included
20 patients with non-Hodgkin’s lymphoma (NHL) (17 males and
3 females). The median age was 53 years (range, 18–66 years).
According to the working formulation, there were 13 patients with
intermediate grade, 6 with high grade, and 1 with low grade.
Age-adjusted IPI analysis showed 8 patients with 1 risk factor, 10
with 2 risk factors, and 2 with 3 risk factors. After 2 courses of
CDME, the overall and complete response (CR) rates were 65%
and 30%, respectively. Mobilization was successful in all patients.
The median MNC yield was 7.85  108/kg (range, 3.49–20.12),
and CD34 cell yield was 11  106/kg (range, 2.08–38.7). No
factors affect the mobilization outcome after CDME schedule. All
patients received high-dose chemotherapy and autologous periph-
eral blood stem cell transplantation (PBSCT), and 1 toxicity-
related death occurred. In autografts carried out using CDME-
mobilized PBSC, the median time to neutrophils  500/mm3 was
10 days (range, 1–44 days) and that to platelets  20,000/mm3 was
11 days (range, 2–47 days). The overall response rate was 78.9%
(CR 68.4% and PR 10.5%), and median PFS and OS were 9 and
16 months, respectively, after PBSCT. In multivariate analysis,
ECOG performance status, age-adjusted IPI, and disease status
before transplantation were signiﬁcantly associated with PFS and
OS. Our results demonstrate that the CDME regimen is effective
in refractory or relapsed NHL, resulting in successful stem cell
mobilization.
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GM-CSF AND INTERFERON- MAINTENANCE THERAPY FOR MULTIPLE
MYELOMA PATIENTS AFTER AUTOLOGOUS STEM CELL TRANSPLANTA-
TION (ASCT): AN INTERIM REPORT
Gowda, S., Cogle, C.R., Khan, S.A., Moreb, J.S. University of Florida,
College of Medicine, Gainesville, FL.
Maintenance therapy with IFN-	 has been shown to delay mul-
tiple myeloma (MM) relapse with variable effect on overall sur-
vival. In our experience, 30% of patients are unable to effectively
take IFN-	 after ASCT because of IFN-	–induced cytopenias. We
hypothesize that the inclusion of GM-CSF will prevent the my-
elosuppresion by IFN-	 and may further improve the clinical
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outcome in MM patients. Between January 2003 and September
2004, 13 MM patients received GM-CSF and IFN-	 therapy
following ASCT. IFN-	 was started within 120 days after ASCT at
a dose of 1 million units and increased as tolerated to 4 million
units subcutaneously 3  per week. GM-CSF was started at 125
g/m2day subcutaneously on the same days with IFN-	. The
combination therapy continued for 1 year, after which GM-CSF
was stopped. Ten patients receiving this combination therapy (me-
dian age, 61 years) were evaluable for analysis. Disease status at the
time of enrollment was complete remission in 1 patient, partial
remission in 4 patients, and very good partial remission in 5
patients. Six patients had stage III and 4 had stage II, with only 1
in renal failure. Median follow-up from last ASCT was 16 months.
Median duration of combination therapy was 7.5 months (range,
1–12 months). The median tolerated dose of IFN-	 was 4 million
units, although 2 patients had a permanent dose reduction to 2 or
3 million units due to ﬂu-like symptoms. None of the patients
dropped from the trial secondary to myelosuppression. Three
patients dropped out due to persistent ﬂu-like symptoms or ele-
vated liver function tests secondary to IFN-	, 2 patients dropped
out due to disease progression, and 1 patient had a GM-CSF dose
reduction due to leukocytosis. Median PLT count and ANC at 3
months were 136,000/L and 3800/L, respectively. One patient
required Procrit therapy. All patients received GM-CSF and
IFN-	 therapy for a minimum of 34 days. Two patients improved
to CR from PR and VGPR, 2 patients progressed, 5 patients
remained stable, and 1 patient was lost to follow-up. Using the
method of Kaplan and Meier, median PFS and OS for the whole
group have not been reached. In a previous analysis of 25 similar
patients who received a median of 8 months of IFN-	–only main-
tenance therapy (median tolerated dose of 3 million units), 10
patients had to discontinue therapy due to myelosuppression. In
conclusion, the addition of GM-CSF to IFN-	 is well tolerated
and is very effective in preventing IFN-induced myelosuppression.
It is too early to tell whether a survival beneﬁt will be realized.
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A PHASE II STUDY OF XCELLERATED T CELLS IN PATIENTS WITH RE-
LAPSED OR REFRACTORY INDOLENT NON-HODGKIN’S LYMPHOMA (NHL)
Gribben, J.G.1, Bartlett, N.L.2, Stephenson, J.J.3, Milder, M.S.4,
Boccia, R.V.5, Redfern, C.6, Mizuno, V.M.7, Berenson, R.J.7,
Frohlich, M.W.7 1Dana Farber Cancer Institute, Boston, MA; 2Wash-
ington University School of Medicine, St. Louis, MO; 3Cancer Centers of
the Carolinas, Greenville, SC; 4The Swedish Cancer Institute, Seattle,
WA; 5Center for Cancer & Blood Disorders, Bethesda, MD; 6Sharp
Healthcare, San Diego, CA; 7Xcyte Therapies, Inc., Seattle, WA.
Background: T cells can be activated and expanded ex vivo using
the Xcellerate™ process, in which peripheral blood mononuclear
cells (PBMCs) are incubated with anti-CD3 and anti-CD28 anti-
body–coated magnetic beads (Xcyte™ Dynabeads). In an ongo-
ing trial of Xcellerated t cells in subjects with chronic lymphocytic
leukemia, marked and sustained reductions in lymphadenopathy
and splenomegaly were observed. This study is designed to deter-
mine whether similar effects can be observed in subjects with
indolent NHL. Methods: Subjects must have relapsed or refrac-
tory indolent NHL. PBMCs are collected by leukapheresis for the
Xcellerate™ process, and subjects subsequently receive 2 infusions
of 20–60  109 Xcellerated t cells separated by 6–8 weeks. Ap-
proximately 40 subjects will be treated. Results: Twenty subjects
have been enrolled. The median number of prior treatment regi-
mens was 3 (range, 1–4). Histological subtypes are small lympho-
cytic (n  9), follicular (n  5), mantle cell (n  4), and marginal
zone (n  2). Xcellerated t cells have been manufactured in 15
subjects to date, and 13 subjects have been treated. No related
serious adverse events have been reported to date. Follow-up is
available in 8 subjects through week 6. In these subjects, the
median number of cells infused was 39 109 (range, 33–39 109),
of which 98.9  0.2% were T cells (mean  SD). T-cell counts
increased from 728 56/mm3 before infusion to 1251 953/mm3
on day 28 (mean  SD). All 3 SLL subjects had marked reductions
in peripheral lymphadenopathy on physical examination, and 2 of
these patients also showed decreases on computed tomography
scan. However, the patients did not meet radiographic criteria for
response; 2 of them had bulky abdominal lymphadenopathy. A
bone marrow biopsy specimen obtained in 1 of the SLL subjects
revealed a decrease in leukemic involvement from 70% to 40% of
cellularity. In 2 subjects with follicular lymphoma, 1 had stable
disease radiographically and 1 had disease progression. Three sub-
jects with mantle cell lymphoma had progressive disease. Conclu-
sions: Xcellerated t cells can be manufactured in subjects with
indolent NHL. Treatment leads to signiﬁcant increases in T-cell
counts. Preliminary data suggest a reduction in peripheral lymph-
adenopathy and bone marrow involvement in SLL subjects. Data
on additional subjects will be presented.
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A PHASE I/II STUDY OF XCELLERATED T CELLS AFTER AUTOLOGOUS
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS
WITH MULTIPLE MYELOMA
Vij, R.1, Vescio, R.A.2, Borrello, I.M.3, Martin, T.G.4, Siegel, D.5,
Berenson, J.R.6, Janmohamed, F.7, Berenson, R.J.7, Frohlich, M.W.7
1Washington University School of Medicine, St. Louis, MO; 2Cedars-
Sinai Medical Center, Los Angeles, CA; 3Johns Hopkins School of
Medicine, Baltimore, MD; 4University of California, San Francisco,
School of Medicine, San Francisco, CA; 5Hackensack University Medical
Center, Hackensack, NJ; 6Oncotherapeutics, West Hollywood, CA;
7Xcyte Therapies, Inc., Seattle, WA.
Background: Previous studies have demonstrated a correlation
between survival and lymphocyte recovery following autologous
transplantation in subjects with multiple myeloma and other ma-
lignancies. We initiated a trial in the transplantation setting to
evaluate the activity of T cells activated and expanded ex vivo with
the Xcellerate™ process, which uses anti-CD3 and anti-CD28
antibody–coated magnetic beads (Xcyte™ Dynabeads). Meth-
ods: After induction therapy, patients underwent leukapheresis to
collect peripheral blood mononuclear cells for the Xcellerate™
process. Patients then underwent stem cell mobilization and col-
lection, followed by high-dose melphalan (200 mg/m2). Three days
after peripheral blood stem cell infusion, subjects received 50–
100  109 Xcellerated T cells. Results: A total of 36 subjects were
treated. The median last follow-up visit is 360 days posttransplan-
tation (range, 180–630 days). A WaveBioreactor-based Xcellerate
III™ process, which was instituted in the last 18 subjects, resulted
in a 249-  90-fold (mean  SD) T-cell expansion. An average of
93.6  0.8  109 cells was infused, of which 97.6  4.0% were T
cells. There were no grade 3 or 4 acute infusional toxicities.
Median days of neutropenia and thrombocytopenia were 5 (range,
3–43 days) and 4.5 (range, 0–128 days), respectively. Median days
of hospitalization were 16 (range, 10–70 days). Lymphocyte re-
covery was rapid, with counts reaching  500/mm3 generally
within 1–2 days after T-cell infusion. Historically, lymphocyte
recovery to 500/mm3 usually does not occur for 3 or more weeks
posttransplantation. The rapid lymphocyte recovery included both
CD4 and CD8 T cells. The mean ( SEM) CD4 T-cell
count at 90 days posttransplantation was 1210  80/mm3, which is
signiﬁcantly higher than that for historical controls receiving the
same treatment regimen without Xcellerated T cells (198  72/
mm3). In 35 evaluable patients, preliminary results demonstrated
9% CRs, 51% VGPRs, 29% PRs, and 11% with PD, using the
M-protein at diagnosis as a reference. Conclusions: In multiple
myeloma subjects, administration of Xcellerated T cells after high-
dose chemotherapy and autologous stem cell transplantation leads
to rapid lymphocyte recovery. Most subjects achieve clinical re-
sponses in the autologous transplantation setting.
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HIGH-DOSE MELPHALAN (HDM) WITHOUT HEMATOPOIETIC PROGENI-
TOR CELL (HPC) SUPPORT FOR TREATMENT OF PLASMA CELL LEUKEMIA
Hayek, F.N., Al-Ghawi, H., Mehta, A., Herzig, R.H., Herzig, G.P.
University of Louisville, James Graham Brown Cancer Center, Louis-
ville, KY.
Primary plasma cell leukemia (PPCL) is a rare subtype of mul-
tiple myeloma that follows a rapid clinical course and responds
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